“…[ 17 ] Hospital | 342 | Abbott M2000 SARS-CoV-2 assay, Abbott Park, IL, USA | N, RdRp | Nasopharyngeal | NR | NR | Epidemiological trends and anticipating the next phase of the pandemic using median weekly incident hospitalizations due to SARS-CoV-2 infection in Massachusetts, obtained from the Massachusetts Department of Public Health | NR | NR | No predictive modeling used in this study A strong inverse correlation (Pearson's correlation r = −0.76 ( P < 0.05)) was observed between the median Ct value and median weekly incident hospitalizations due to SARS-CoV-2 infection in Massachusetts, obtained from the Massachusetts Department of Public Health | Phillips et al. [ 13 ] | Hospital | 2114 Lowest Ct value associated > 0 for E and N2 region for Xpert Xpress SARSCoV-2 assay OR a single Ct value that corresponds to the lowest Ct value > 0 for the Xpert Xpress SARS-CoV-2/Flu/RSV assay | Xpert Xpress SARS-CoV-2 Assay, Cepheid, Sunnyvale CA, USA Xpert Xpress SARS-CoV-2/Flu/RSV assay, Cepheid, Sunnyvale CA, USA Both run on Infinity and XVI systems | E, N2 | Nasopharyngeal or anterior nasal | NR | NR | Future changes in institutional COVID-19 cases | NR | 2 weeks | When compared temporally, the average weekly Ct values for all tests performed negatively correlated with the number of cases occurring 2 weeks after specimen collection (Pearson’s correlation r = –0.75, P < 0.0001) Predictive modeling using Ct values from the epidemic surge October 2020–March 2021 correctly predicted whether cases would increase or decrease 65% of the time for a subsequent surge (May–July 2021) |
Stevens et al. [ 23 ] | Hospital and public | ~ 26,388 | Five testing platforms used: BD Max; Liat, Roche Diagnostics; Cobas, Roche Diagnostics; GeneSig, Primerdesign; Seegene, Korea | E, M, N, N1, N2, ORF1a ORF1a and N gene RdRp and N gene | NR | NR | Omicron strain (B.1.1.529) and Omicron BA.2 sub-variant | Community prevalence | |
…”